Valmark Advisers’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-9,202
Closed -$314K – 435
2021
Q4
$314K Buy
9,202
+570
+7% +$22.3K 0.01% 341
2021
Q3
$416K Hold
8,632
– – 0.01% 295
2021
Q2
$390K Hold
8,632
– – 0.01% 300
2021
Q1
$416K Hold
8,632
– – 0.01% 291
2020
Q4
$465K Buy
8,632
+167
+2% +$7.55K 0.01% 263
2020
Q3
$312K Hold
8,465
– – 0.01% 232
2020
Q2
$262K Hold
8,465
– – 0.01% 230
2020
Q1
$234K Buy
+8,465
New +$254K 0.01% 210

Other funds holding NEO

Valmark Advisers's NEO Position: Q1 2022 in Review

Valmark Advisers sold out of NeoGenomics (NEO) in Q1 2022, closing a stake of 9,202 shares — an estimated $314K sold.

Valmark Advisers first reported a position in NEO in Q1 2020 and held it in 8 quarters. The position peaked at $465K in Q4 2020. 279 funds tracked by Wall St. Rank hold NEO as of Q1 2022.

  • Valmark Advisers reported no remaining NeoGenomics position as of Q1 2022 after selling out during the quarter.
  • Valmark Advisers sold 9,202 NeoGenomics shares in Q1 2022, an estimated $314K.
  • Valmark Advisers first reported a position in NeoGenomics in Q1 2020 and held it in 8 quarters.
  • Valmark Advisers's NeoGenomics position peaked at $465K in Q4 2020.
  • 279 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2022.

Based on Valmark Advisers's 13F filing for Q1 2022, filed 10 May 2022.